Stay updated on Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Sign up to get notified when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.
Latest updates to the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page
- Check3 days agoChange DetectedAdded a dedicated Locations section with Georgia as a location, and updated the page revision to v3.3.3. Removed the separate Georgia Locations header and the HHS Vulnerability Disclosure link.SummaryDifference0.2%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedNon-significant editorial changes were made, including notes that publications are provided voluntarily and may be auto-filled from PubMed and the addition of a Revision: v3.3.2 label; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check39 days agoChange DetectedRemoved the government funding status notice banner from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check54 days agoChange DetectedStudy details and eligibility appear unchanged; formatting and layout updates are minor. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check82 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%
- Check90 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%
Stay in the know with updates to Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.